Related Experiment Video

Updated: May 24, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

Decrease in TSH Receptor Autoantibodies during Antithyroid Treatment: Relationship with a Long Noncoding Heg RNA and

Niels Juel Christensen1, Gurli Habekost, Palle Bratholm

  • 1Endocrine Research Laboratory, Medical Department O, Herlev Hospital, University of Copenhagen, 2730 Herlev, Denmark.

ISRN Endocrinology
|February 25, 2012
PubMed

Insights

Long noncoding RNA Heg and Cdk1 gene expression influence TSH receptor autoantibodies (TRAb) in Graves' disease. Heg RNA inversely correlates with TRAb, while Cdk1 expression positively correlates, with both changing during treatment.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Immunology

Background:

  • Graves' disease is an autoimmune disorder characterized by elevated TSH receptor autoantibodies (TRAb).
  • Previous studies indicated a negative correlation between long noncoding RNA Heg and TRAb in untreated patients.
  • The role of gene expression, specifically Cdk1, in relation to TRAb levels remained unclear.

Purpose of the Study:

  • To investigate the relationship between Cdk1 gene expression and TRAb concentrations in Graves' disease.
  • To explore the influence of Heg RNA and Cdk1 mRNA on TRAb levels during disease progression and treatment.
  • To elucidate the distinct mechanisms by which Heg RNA and Cdk1 mRNA may affect TRAb.

Main Methods:

  • Analysis of Heg RNA and Cdk1 mRNA expression in mononuclear cells from Graves' disease patients and controls.
  • Correlation analysis between RNA levels and TRAb concentrations in untreated and treated patients.
  • Comparison of RNA levels before and after antithyroid drug treatment.

Main Results:

  • Cdk1 gene expression in mononuclear cells is positively associated with TRAb levels in untreated Graves' disease patients.
  • Heg RNA levels remain unchanged during antithyroid drug treatment, while Cdk1 mRNA significantly decreases.
  • Cdk1 mRNA levels in treated patients fall below those observed in normal subjects.

Conclusions:

  • Both Heg RNA and Cdk1 mRNA play a role in modulating TSH receptor autoantibodies in Graves' disease.
  • Heg RNA and Cdk1 mRNA appear to influence TRAb levels through distinct mechanisms.
  • Cdk1, involved in cell cycle regulation, shows a significant decrease during treatment, suggesting its involvement in TRAb reduction.

More Related Videos

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Related Concept Videos

Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...